Product Description
Mechanisms of Action: IFNA Inhibitor
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Lupus Erythematosus, Systemic|Myositis
Phase 1: Lupus Erythematosus, Systemic|Polymyositis|Dermatomyositis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
MI-CP212 | P2 |
Completed |
Myositis|Lupus Erythematosus, Systemic |
2015-03-01 |
|
2010-024069-30 | P2 |
Completed |
Lupus Erythematosus, Systemic |
2014-04-17 |
|
CD-IA-MEDI-545-1067 | P2 |
Completed |
Lupus Erythematosus, Systemic |
2013-11-14 |
|
D2800C00001 | P2 |
Completed |
Lupus Erythematosus, Systemic |
2012-11-07 |